Evidence map›Paper›PMID 38618821›Full record

ReviewInternational journal of health policy and management2023

Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis.

Anju Murayama, Sae Kamamoto, Hiroaki Saito, Erika Yamashita, Yosuke Suzuki, Tetsuya Tanimoto, Piotr Ozieranski, Akihiko Ozaki

Abstract readReview
In one paragraph

Review in International journal of health policy and management, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anju MurayamaTohoku University School of Medicine, Sendai, Japan.ORCID 0000-0002-4279-4748
Sae KamamotoMedical Governance Research Institute, Tokyo, Japan.
Hiroaki SaitoDepartment of Internal Medicine, Soma Central Hospital, Soma, Japan.ORCID 0000-0002-0824-454X
Erika YamashitaMedical Governance Research Institute, Tokyo, Japan.
Yosuke SuzukiMedical Governance Research Institute, Tokyo, Japan.
Tetsuya TanimotoDepartment of Internal Medicine, Navitas Clinic Kawasaki, Kawasaki, Japan.ORCID 0000-0002-9818-8587
Piotr OzieranskiDepartment of Social and Policy Sciences, University of Bath, Bath, UK.ORCID 0000-0002-2023-3288
Akihiko OzakiDepartment of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan.ORCID 0000-0003-4415-9657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFinancial relationships between healthcare institutions and pharmaceutical companies can lead to conflicts of interest (COIs), potentially compromising patients' care. In Japan, scholarship donations, unique type of payments made to healthcare institutions and their subunits by pharmaceutical industries without restricting their use including non-educational or research purpose, may often have implicit promotional purposes. However, detailed information about these payments remains scarce.

methodsThis study employed a cross-sectional design to analyse the extent and distribution of all scholarship donations made by all 73 pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association (JPMA) to healthcare institutions in 2017. Data were obtained from publicly available sources from the companies, and the total number of payments, their distributions across various institutions and specialties were analysed.

resultsA total of 27 007 payment contracts amounting to $178 703 721 in scholarship donations were made to 4839 specific departments and laboratories at 251 different institutions by 67 pharmaceutical companies. National universities received 50.8% of total payments. All universities setting medical school in Japan received one or more payments. Domestic pharmaceutical companies contributed to $137 797 302 (77.1%) in total. Clinical medicine departments received 89.6% ($160 113 147) with 6.2% ($11 011 946) and 2.0% ($3 600 456) allocated to basic medicine and social medicine specialties, respectively.

conclusionThis study provided a comprehensive overview of scholarship donations from pharmaceutical companies to healthcare institutions in Japan, revealing significant financial support primarily directed to national universities and clinical medicine departments. Japanese policy-makers should consider implementing regulations that promote transparency and mitigate potential COIs arising from scholarship donations, which may be useful in other countries with similar schemes.

Indexed as

Delivery of Health CareFellowships and ScholarshipsCross-Sectional StudiesHumansJapanPharmaceutical PreparationsPharmaceutical PreparationsHealth PolicyInstitutional Conflicts of InterestJapanNon-research PaymentPharmaceutical PaymentTransparency

Identifiers

PMID38618821
PMCPMC10590253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.